Compare LITM & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LITM | NRXS |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.7M | 46.3M |
| IPO Year | N/A | N/A |
| Metric | LITM | NRXS |
|---|---|---|
| Price | $2.91 | $5.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 524.6K | 83.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $31.05 |
| Revenue Next Year | N/A | $146.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.34 | $1.33 |
| 52 Week High | $10.38 | $6.20 |
| Indicator | LITM | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 43.70 | 69.91 |
| Support Level | $2.91 | $4.50 |
| Resistance Level | $3.12 | $4.50 |
| Average True Range (ATR) | 0.30 | 0.38 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 22.73 | 92.49 |
Snow Lake Resources Ltd is a Canadian nuclear fuel cycle and critical minerals company with a portfolio of U.S.-focused uranium projects, including the Pine Ridge Uranium Project in the Powder River Basin in Wyoming. The company also holds exploration-stage critical minerals projects including the Snow Lake Lithium Project, Shatford Lake Lithium Project, and Engo Valley Uranium Project in Manitoba, Canada, and Namibia. Snow Lake has investments in companies with critical minerals assets, including rare earths and lithium in North America. The primary commercial use for U3O8 is as fuel for nuclear power plants to generate electricity.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).